Tissueblue Injection, Solution
FDA Label NDC 68803-722

Full FDA labeling including Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by D.o.r.c. Dutch Ophthalmic Research Center (international) B.v. for the product Tissueblue (NDC 68803-722). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding tissueblue 0.025% - indications & usage section, tissueblue 0.025% - dosage & administration section, tissueblue 0.025% - dosage forms & strengths section, tissueblue 0.025% - contraindications section, tissueblue 0.025% - warnings and precautions section, tissueblue 0.025% - adverse reactions section, tissueblue 0.025% - pregnancy section, tissueblue 0.025% - lactation section, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Tissueblue 0.025% - Lactation Section

Risk Summary
No data are available regarding the presence of Brilliant Blue G in human milk after intraocular administration of TissueBlue 0.025%, or the effects on the breastfed infant or the effects on milk production. However, breastfeeding is not expected to result in exposure of the child to Brilliant Blue G due to the expected negligible systemic exposure of BBG in humans following intravitreal injection and subsequent removal of the drug at the completion of surgical procedures.

Tissueblue 0.025% - Nonclinical Toxicology Section

Studies to evaluate the potential for carcinogenicity or impairment of fertility of TissueBlue 0.025% have not been conducted.
Brilliant Blue G was not mutagenic in the Ames assay, the in vitro mouse lymphoma assay, or the in vivo rat micronucleus assay.

* Please review the disclaimer below.